These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9631932)

  • 1. Improved cross-reactivity to alpha OH triazolam in the BMC CEDIA DAU urine benzodiazepine assay.
    Fraser AD; Meatherall R
    Ther Drug Monit; 1998 Jun; 20(3):331-4. PubMed ID: 9631932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and GC-MS cut-off values.
    Fraser AD; Meatherall R
    J Anal Toxicol; 1996; 20(4):217-23. PubMed ID: 8835658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEDIA dau Benzodiazepine screening assay: a reformulation.
    Meatherall RC; Fraser AD
    J Anal Toxicol; 1998; 22(4):270-3. PubMed ID: 9681328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIMS, CEDIA, and HS-CEDIA immunoassays are inadequately sensitive for detection of benzodiazepines in urine from patients treated for chronic pain.
    Darragh A; Snyder ML; Ptolemy AS; Melanson S
    Pain Physician; 2014; 17(4):359-66. PubMed ID: 25054395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
    Fraser AD; Howell P
    J Anal Toxicol; 1998; 22(1):50-4. PubMed ID: 9491969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary screening for alpha-OH triazolam by FPIA and EIA with confirmation by GC/MS.
    Fraser AD; Bryan W; Isner AF
    J Anal Toxicol; 1992; 16(6):347-50. PubMed ID: 1293398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary screening for alprazolam, triazolam, and their metabolites with the EMIT d.a.u. benzodiazepine metabolite assay.
    Fraser AD
    J Anal Toxicol; 1987; 11(6):263-6. PubMed ID: 3323671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cross-reactivity of Instant-View M-1 for detection of benzodiazepine-related drugs and their metabolites in urine].
    Torikoshi A; Namera A; Arima Y; Toubou H; Tajima T; Shiraishi H; Nagao M
    Chudoku Kenkyu; 2014 Mar; 27(1):33-8. PubMed ID: 24724359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limitations of EMIT benzodiazepine immunoassay for monitoring compliance of patients with benzodiazepine therapy even after hydrolyzing glucuronide metabolites in urine to increase cross-reactivity: comparison of immunoassay results with LC-MS/MS values.
    Dixon RB; Floyd D; Dasgupta A
    Ther Drug Monit; 2015 Feb; 37(1):137-9. PubMed ID: 25004136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved CEDIA benzodiazepine assay eliminates sertraline crossreactivity.
    Fitzgerald RL; Herold DA
    J Anal Toxicol; 1997; 21(1):32-5. PubMed ID: 9013289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine benzodiazepine screening using Roche Online KIMS immunoassay with beta-glucuronidase hydrolysis and confirmation by gas chromatography- mass spectrometry.
    Klette KL; Wiegand RF; Horn CK; Stout PR; Magluilo J
    J Anal Toxicol; 2005 Apr; 29(3):193-200. PubMed ID: 15842763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays.
    Pettersson Bergstrand M; Helander A; Hansson T; Beck O
    Drug Test Anal; 2017 Apr; 9(4):640-645. PubMed ID: 27366870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid determination of benzodiazepines, zolpidem and their metabolites in urine using direct injection liquid chromatography-tandem mass spectrometry.
    Jeong YD; Kim MK; Suh SI; In MK; Kim JY; Paeng KJ
    Forensic Sci Int; 2015 Dec; 257():84-92. PubMed ID: 26282513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of benzodiazepine intake in therapeutic doses by immunoanalysis of urine: two techniques evaluated and modified for improved performance.
    Beck O; Lafolie P; Hjemdahl P; Borg S; Odelius G; Wirbing P
    Clin Chem; 1992 Feb; 38(2):271-5. PubMed ID: 1541010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of four immunoassay screening kits for the detection of benzodiazepines in urine.
    DeRienz RT; Holler JM; Manos ME; Jemionek J; Past MR
    J Anal Toxicol; 2008; 32(6):433-7. PubMed ID: 18652750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoassay detection of benzodiazepines and benzodiazepine metabolites in blood.
    Huang W; Moody DE
    J Anal Toxicol; 1995 Oct; 19(6):333-42. PubMed ID: 8926726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids.
    Berg JA; Schjøtt J; Fossan KO; Riedel B
    Subst Abuse Rehabil; 2015; 6():131-9. PubMed ID: 26604854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of assay methods for benzodiazepines in urine. A receptor assay, two immunoassays, and gas chromatography-mass spectrometry.
    Nishikawa T; Ohtani H; Herold DA; Fitzgerald RL
    Am J Clin Pathol; 1997 Mar; 107(3):345-52. PubMed ID: 9052386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four immunoassays for the detection of lorazepam in urine.
    Meatherall R; Fraser AD
    Ther Drug Monit; 1998 Dec; 20(6):673-5. PubMed ID: 9853986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug screening in urine by cloned enzyme donor immunoassay (CEDIA) and kinetic interaction of microparticles in solution (KIMS): a comparative study.
    Schwettmann L; Külpmann WR; Vidal C
    Clin Chem Lab Med; 2006; 44(4):479-87. PubMed ID: 16599844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.